AU000000TLX2
© PR Newswire
18.03.2025
TLX
LISTED
ASX
Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
News Preview
MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or 'ANVISA') has approved Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide i...
Themefolio
Profiler
Peergroup
© PR Newswire
17.03.2025
TLX
LISTED
ASX
Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
News Preview
MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or 'ANVISA') has approved Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide i...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.03.2025
TLX
LISTED
ASX
Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
News Preview
MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or ‘ANVISA’) has approved Illuccix® (kit for the preparation of gallium-68...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
13.03.2025
TLX
LISTED
ASX
Telix Adds Lead-212 Isotope Production Capability
News Preview
MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated a breakthrough generator technology for the production of lead-212 (212Pb) and successfully completed first production.
The new generator technology, d...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
12.03.2025
TLX
LISTED
ASX
Telix Adds Lead-212 Isotope Production Capability
News Preview
MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated a breakthrough generator technology for the production of lead-212 (212Pb) and successfully completed first production....
Themefolio
Profiler
Peergroup
© Globe Newswire
12.03.2025
TLX
LISTED
ASX
Telix Adds Lead-212 Isotope Production Capability
News Preview
MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated a breakthrough generator technology for the production of lead-212 (212Pb) and successfully completed first production....
Themefolio
Profiler
Peergroup
© PR Newswire
03.03.2025
TLX
LISTED
ASX
Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Ind., March 4, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) invites investors to join a webinar showcasing the Company's late-stage and next-generation radiotherapeutic candidates in urologic oncology....
Themefolio
Profiler
Peergroup
© Globe Newswire
03.03.2025
TLX
LISTED
ASX
Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
News Preview
MELBOURNE, Australia and INDIANAPOLIS, March 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) invites investors to join a webinar showcasing the Company’s late-stage and next-generation radiotherapeutic candidates in urologic oncology....
Themefolio
Profiler
Peergroup
© PR Newswire
26.02.2025
TLX
LISTED
ASX
FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review
News Preview
MELBOURNE, Australia, Feb. 26, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for its breakthrough investigational kidney cancer PET[1] imaging agent TLX250-CDx (Zir...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.02.2025
TLX
LISTED
ASX
FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for its breakthrough investigational kidney cancer PET1 imaging age...
Themefolio
Profiler
Peergroup
© PR Newswire
25.02.2025
TLX
LISTED
ASX
Illuccix® Prostate Cancer Imaging Agent Approved in Luxembourg
News Preview
MELBOURNE, Australia, Feb. 25, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by ALMPS[2] for the detection and localization o...
Themefolio
Profiler
Peergroup
© PR Newswire
24.02.2025
TLX
LISTED
ASX
Telix's Illuccix® PSMA-PET Imaging Agent Approved in Norway
News Preview
MELBOURNE, Australia, Feb. 24, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by NOMA[2] for the detection and localization of...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
20.02.2025
TLX
LISTED
ASX
Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Ind., Feb. 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces its financial results for the year ended 31 December 2024. All figures are in AU$ unless stated otherwise.
FY2024 highlights
Total revenue, driven primarily from sales of Illuccix® o...
Themefolio
Profiler
Peergroup
© PR Newswire
20.02.2025
TLX
LISTED
ASX
Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Ind., Feb. 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces its financial results for the year ended 31 December 2024. All figures are in AU$ unless stated otherwise....
Themefolio
Profiler
Peergroup
© Globe Newswire
20.02.2025
TLX
LISTED
ASX
Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces its financial results for the year ended 31 December 2024. All figures are in AU$ unless stated otherwise....
Themefolio
Profiler
Peergroup
© PR Newswire
12.02.2025
TLX
LISTED
ASX
Illuccix® Approved in the United Kingdom
News Preview
MELBOURNE, Australia, Feb. 12, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent Illuccix® (kit...
Themefolio
Profiler
Peergroup
© PR Newswire
12.02.2025
TLX
LISTED
ASX
Illuccix® Approved in the United Kingdom
News Preview
MELBOURNE, Australia, Feb. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent Illuccix® (kit...
Themefolio
Profiler
Peergroup
© PR Newswire
30.01.2025
TLX
LISTED
ASX
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Jan. 31, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has completed the acquisition from antibody engineering company ImaginAb, Inc. (ImaginAb). The acquisition includes a pipeline of next-generation therapeutic candidates, a proprietary no...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.01.2025
TLX
LISTED
ASX
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has completed the acquisition from antibody engineering company ImaginAb, Inc. (ImaginAb). The acquisition includes a pipeline of next-generation therapeutic candidates, a proprietar...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2025
TLX
LISTED
ASX
Telix Completes Acquisition of RLS (USA) Inc.
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Jan. 28, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has completed the acquisition of RLS (USA) Inc. (RLS; RLS Radiopharmacies), America's only Joint Commission-accredited radiopharmacy network distributing PET[1], SPECT[2] and therapeutic...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2025
TLX
LISTED
ASX
Telix Completes Acquisition of RLS (USA) Inc.
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has completed the acquisition of RLS (USA) Inc. (RLS; RLS Radiopharmacies), America’s only Joint Commission-accredited radiopharmacy network distributing PET1, SPECT2 and therapeutic...
Themefolio
Profiler
Peergroup
© PR Newswire
23.01.2025
TLX
LISTED
ASX
ImaginAb, Inc. Innovative Biologics-Technologieplattform von Telix erworben, um die Entdeckung von therapeutischen Wirkstoffen der nächsten Generation zu ermöglichen
News Preview
INGLEWOOD, Kalifornien, 23. Januar 2025 /PRNewswire/ -- ImaginAb, Inc., gibt bekannt, dass es eine Vereinbarung über den Verkauf einer Pipeline von therapeutischen Kandidaten der nächsten Generation, einer firmeneigenen neuartigen Technologieplattform für Biologika und einer Forschungseinrichtung für Protein-Engineering und -Entdeckung an Telix P...
Themefolio
Profiler
Peergroup
© PR Newswire
22.01.2025
TLX
LISTED
ASX
ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery
News Preview
INGLEWOOD, Calif., Jan. 22, 2025 /PRNewswire/ -- ImaginAb, Inc., announces that it has entered into an agreement to sell a pipeline of next-generation therapeutic candidates, proprietary novel biologics technology platform, and a protein engineering and discovery research facility to Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TXL).
Followi...
Themefolio
Profiler
Peergroup
© PR Newswire
22.01.2025
TLX
LISTED
ASX
ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery
News Preview
INGLEWOOD, Calif., Jan. 22, 2025 /PRNewswire/ -- ImaginAb, Inc., announces that it has entered into an agreement to sell a pipeline of next-generation therapeutic candidates, proprietary novel biologics technology platform, and a protein engineering and discovery research facility to Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TXL)....
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2025
TLX
LISTED
ASX
Illuccix® Receives European Approval
News Preview
MELBOURNE, Australia and LIÈGE, Belgium, Jan. 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 goz...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2025
TLX
LISTED
ASX
Illuccix® Receives European Approval
News Preview
MELBOURNE, Australia and LIÈGE, Belgium, Jan. 17, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 goz...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2025
TLX
LISTED
ASX
Illuccix® Receives European Approval
News Preview
MELBOURNE, Australia and LIÈGE, Belgium, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET1 imaging agent Illuccix® (kit for the preparation of gallium...
Themefolio
Profiler
Peergroup
© PR Newswire
13.01.2025
TLX
LISTED
ASX
Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Jan. 14, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting this week at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA (U.S.A.). ...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2025
TLX
LISTED
ASX
Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting this week at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA (U.S.A.)...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2025
TLX
LISTED
ASX
Telix Exceeds FY24 Guidance with US$142M Q4 Revenue
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended 31 December 2024 (Q4 2024)....
Themefolio
Profiler
Peergroup
© PR Newswire
13.01.2025
TLX
LISTED
ASX
Scintimun® Commercialization Partnership with Curium Pharma
News Preview
MELBOURNE, Australia and LIÈGE, Belgium, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has entered into an agreement with Curium Pharma for the transfer of marketing and distribution rights for Scintimun® (99mTc-besilesomab, also known as TLX66-CDx), a diagnostic ra...
Themefolio
Profiler
Peergroup
© PR Newswire
13.01.2025
TLX
LISTED
ASX
Scintimun® Commercialization Partnership with Curium Pharma
News Preview
MELBOURNE, Australia and LIÈGE, Belgium, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has entered into an agreement with Curium Pharma for the transfer of marketing and distribution rights for Scintimun® (99mTc-besilesomab, also known as TLX66-CDx), a diagnostic ra...
Themefolio
Profiler
Peergroup
© PR Newswire
12.01.2025
TLX
LISTED
ASX
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Jan. 12, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has entered into an asset purchase agreement with antibody engineering company ImaginAb, Inc. (ImaginAb) to acquire a pipeline of next-generation therapeutic candidates, proprietary nove...
Themefolio
Profiler
Peergroup
© PR Newswire
12.01.2025
TLX
LISTED
ASX
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has entered into an asset purchase agreement with antibody engineering company ImaginAb, Inc. (ImaginAb) to acquire a pipeline of next-generation therapeutic candidates, proprietary nove...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2025
TLX
LISTED
ASX
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has entered into an asset purchase agreement with antibody engineering company ImaginAb, Inc. (ImaginAb) to acquire a pipeline of next-generation therapeutic candidates, proprietary...
Themefolio
Profiler
Peergroup
© PR Newswire
30.12.2024
TLX
LISTED
ASX
NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports
News Preview
MELBOURNE, Australia and BRUSSELS, Dec. 31, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) and the Brussels-based Oncidium foundation today announce that results for the NOBLE Registry of TLX599-CDx (99mTc-iPSMA) have been published in the European Journal of Nuclear Medicine and Molecular Imaging (...
Themefolio
Profiler
Peergroup
© PR Newswire
30.12.2024
TLX
LISTED
ASX
NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports
News Preview
MELBOURNE, Australia and BRUSSELS, Dec. 30, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) and the Brussels-based Oncidium foundation today announce that results for the NOBLE Registry of TLX599-CDx (99mTc-iPSMA) have been published in the European Journal of Nuclear Medicine and Molecular Imaging (...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.12.2024
TLX
LISTED
ASX
NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports
News Preview
MELBOURNE, Australia and BRUSSELS, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) and the Brussels-based Oncidium foundation today announce that results for the NOBLE Registry of TLX599-CDx (99mTc-iPSMA) have been published in the European Journal of Nuclear Medicine and Molecular Imagi...
Themefolio
Profiler
Peergroup
© PR Newswire
29.12.2024
TLX
LISTED
ASX
Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Dec. 30, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX250-CDx (Zircaix®[1], 89Zr- girentuximab) kidney cancer i...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.12.2024
TLX
LISTED
ASX
Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX250-CDx (Zircaix®1, 89Zr- girentuximab) kidney cancer...
Themefolio
Profiler
Peergroup
© PR Newswire
28.11.2024
TLX
LISTED
ASX
First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients
News Preview
MELBOURNE, Australia, Nov. 28, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) and Grand Pharmaceutical Group Limited (00512.HK, Grand Pharma) today announce that a first patient has been dosed in the Phase III ZIRCON-CP trial of TLX250-CDx positron emission tomography (PET) imaging of clear cell ren...
Themefolio
Profiler
Peergroup
© PR Newswire
19.11.2024
TLX
LISTED
ASX
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
News Preview
MELBOURNE, Australia, Nov. 19, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces it will expand its theranostic pipeline with new assets targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in nuclear medicine. Telix's development program will init...
Themefolio
Profiler
Peergroup
© PR Newswire
18.11.2024
TLX
LISTED
ASX
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
News Preview
MELBOURNE, Australia, Nov. 19, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces it will expand its theranostic pipeline with new assets targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in nuclear medicine. Telix's development program will init...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.11.2024
TLX
LISTED
ASX
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
News Preview
MELBOURNE, Australia, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces it will expand its theranostic pipeline with new assets targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in nuclear medicine. Telix’s development program will...
Themefolio
Profiler
Peergroup
© PR Newswire
13.11.2024
TLX
LISTED
ASX
Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology
News Preview
MELBOURNE, Australia and BERLIN, Germany, Nov. 13, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a technology collaboration and licence agreement with Berlin-based Eckert & Ziegler SE (EZAG) for the use of EZAG's cyclotron-based systems to produce the alpha-emitting...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2024
TLX
LISTED
ASX
Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology
News Preview
MELBOURNE, Australia and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a technology collaboration and licence agreement with Berlin-based Eckert & Ziegler SE (EZAG) for the use of EZAG’s cyclotron-based systems to produce the alpha-emitting isoto...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2024
TLX
LISTED
ASX
Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals
News Preview
MELBOURNE, Australia, Nov. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes the announcement by the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) that it will pay separately for specialised diagnostic radiopharmaceuticals[1] for Medicare Fee for Service patients in the h...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2024
TLX
LISTED
ASX
Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals
News Preview
MELBOURNE, Australia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes the announcement by the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) that it will pay separately for specialized diagnostic radiopharmaceuticals1 for Medicare Fee for Service patients in th...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2024
TLX
LISTED
ASX
Telix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix®
News Preview
MELBOURNE, Australia, Oct. 30, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a partnership with California-based Subtle Medical, Inc. (Subtle Medical) for artificial intelligence (AI)-powered positron emission tomography (PET) imaging with Telix's commercial PSMA-PET[1] product, Illuccix® (68Ga-...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2024
TLX
LISTED
ASX
FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
News Preview
MELBOURNE, Australia, Oct. 24, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TLX101-CDx (Pixclara®[1]), an agent for the imaging of glioma. The application has been granted priority r...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.10.2024
TLX
LISTED
ASX
FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
News Preview
MELBOURNE, Australia, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TLX101-CDx (Pixclara®1), an agent for the imaging of glioma. The application has been granted priority...
Themefolio
Profiler
Peergroup
© PR Newswire
22.10.2024
TLX
LISTED
ASX
Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals
News Preview
MELBOURNE, Australia, Oct. 22, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the spin-off of Rhine Pharma[1], which has the mission of expanding global access to innovative radiopharmaceuticals for cancer imaging and treatment using two generator-produced isotopes, technetium-99m (99mTc) and rhe...
Themefolio
Profiler
Peergroup
© PR Newswire
22.10.2024
TLX
LISTED
ASX
Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals
News Preview
MELBOURNE, Australia, Oct. 22, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the spin-off of Rhine Pharma[1], which has the mission of expanding global access to innovative radiopharmaceuticals for cancer imaging and treatment using two generator-produced isotopes, technetium-99m (99mTc) and rhe...
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2024
TLX
LISTED
ASX
Telix Files Form 20-F Registration Statement for Nasdaq ADS
News Preview
MELBOURNE, Australia, Oct. 18, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that it has publicly filed a Form 20-F registration statement (Registration Statement) with the United States (U.S.) Securities and Exchange Commission (SEC) relating to a proposed listing of American Depository Shares (ADS),...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.10.2024
TLX
LISTED
ASX
Telix Files Form 20-F Registration Statement for Nasdaq ADS
News Preview
MELBOURNE, Australia, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that it has publicly filed a Form 20-F registration statement (Registration Statement) with the United States (U.S.) Securities and Exchange Commission (SEC) relating to a proposed listing of American Depository Shares (A...
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2024
TLX
LISTED
ASX
Telix Q3 2024 Business Update - Quarterly Revenue Exceeds AU$200M
News Preview
MELBOURNE, Australia, Oct. 17, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 30 September 2024 (Q3 2024)....
Themefolio
Profiler
Peergroup
© PR Newswire
16.10.2024
TLX
LISTED
ASX
Telix Featured in 13 Abstracts at the Annual Congress of the European Association of Nuclear Medicine (EANM)
News Preview
MELBOURNE, Australia, Oct. 16, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces thirteen abstract presentations featuring the Company's ongoing theranostic development, medical technologies (MedTech), and research and innovation (R&I) programs at the 37th Annual Congress of the European Associa...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2024
TLX
LISTED
ASX
Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
News Preview
MELBOURNE, Australia, Oct. 8, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Australian Therapeutic Goods Administration (TGA) has approved the use of Illuccix® (kit for the preparation of 68Ga-PSMA-11[1] injection) to select patients for PSMA[2]-targeted radionuclide therapy....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.10.2024
TLX
LISTED
ASX
Health Canada Approves Label Expansion for Telix’s Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
News Preview
MELBOURNE, Australia, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that Health Canada has approved the use of Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) in selecting patients for PSMA1-targeted radionuclide therapy....
Themefolio
Profiler
Peergroup
© PR Newswire
03.10.2024
TLX
LISTED
ASX
First Patient Dosed in Phase II 'CA-NINE' Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
News Preview
MELBOURNE, Australia, Oct. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase II trial exploring the clinical utility of Telix's first-in-class investigational PET[1] agent, TLX250-CDx (89Zr-girentuximab) in recurrent clear cell renal cell carcinoma...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
